Prediction: This Biotech Stock Is Heading for a Once-in-a-Generation Opportunity

Source The Motley Fool

Biotech companies have brought many important treatments to market, from ones that address rare diseases to ones that handle common health problems. Vertex Pharmaceuticals (NASDAQ: VRTX) has stood out over the past several years as a top biotech player, thanks to its work in the area of cystic fibrosis (CF). The company's portfolio of treatments is changing the lives of patients and bringing in blockbuster revenue -- in the most recent quarter, product revenue climbed in the double digits to nearly $2.8 billion.

In recent years, investors appreciated Vertex's dominance in the CF market, but some worried about the company's focus on only one treatment area. These days, though, Vertex is on the path to eliminating those worries. Earlier this year, it launched a treatment for blood disorders, and today it's about to address one of the world's most common health problems -- a market where need is particularly high. My prediction is that Vertex is heading for a once-in-a-generation opportunity, and investors who get in on the stock today should benefit for years to come. Let's find out more.

Person talking on the phone.

Image source: Getty Images.

A "multibillion-dollar franchise" for Vertex

I call this a once-in-a-generation opportunity because it isn't every day that a company launches a drug that may tackle a problem plaguing so many. Serving this market should, as Vertex says, result in a "multibillion-dollar franchise" for the company.

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, for the treatment of acute pain. The FDA has pledged to issue a decision by the target date of Jan. 30.

In the U.S. alone, more than 80 million people annually ask their doctors for prescriptions to treat moderate to severe acute pain, and the problem is that options are limited. Over-the-counter pills aren't always effective, and opioid prescription drugs come with the risk of addiction. Vertex has developed a non-opioid candidate, therefore eliminating addiction risk. At the same time, the drug has demonstrated strong efficacy in clinical trials. Suzetrigine works by stopping the sodium channel known as NaV1.8 from transmitting pain signals.

Vertex has already prepared for a potential FDA nod, with teams hired, trained, and ready for launch. The company's two initial goals are to ensure retail distribution across the U.S. and create a financial assistance program to immediately support patient access. Suzetrigine is an oral treatment and doesn't require patients to take any particular tests before giving it a try. These elements should favor a rapid launch.

Legislation is another element that may help suzetrigine. The NOPAIN Act, which goes into effect at the start of the year, offers an add-on payment for the prescription of non-opioids in hospital outpatient and ambulatory surgery settings.

More to come...

All this sounds great, but this may be just the beginning for suzetrigine and Vertex's pain portfolio. The company has launched a phase 3 program for suzetrigine in diabetic peripheral neuropathic pain. This indication represents a potential patient group of 2 million in the U.S. The company has also completed a phase 2 trial for suzetrigine in a type of back pain called lumbosacral radiculopathy. About 4 million Americans seek prescriptions for this type of peripheral neuropathic pain every year. Meanwhile, Vertex continues to study other pain candidates and says its goal is "to fundamentally change the way pain is treated."

The sheer size of the pain market -- and I've just spoken about the U.S. here -- is so vast that addressing it with a safe and effective product could be a game changer for patients, and for Vertex and its investors. It's important to remember that Vertex is already a successful biotech player, bringing in blockbuster revenue thanks to its CF program. And the company has more than $11 billion in cash, meaning it has what it takes to shepherd pain and other candidates through the pipeline or even acquire new programs when the opportunity arises.

So, Vertex's complete picture looks bright. On top of this, my prediction that Vertex is heading for a once-in-a-generation opportunity right now could make that picture even brighter. The pain portfolio could drive a new era of growth in earnings and stock performance, making now a great time to buy Vertex shares and hold on for the long term.

Should you invest $1,000 in Vertex Pharmaceuticals right now?

Before you buy stock in Vertex Pharmaceuticals, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $890,169!*

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.

See the 10 stocks »

*Stock Advisor returns as of November 11, 2024

Adria Cimino has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends Vertex Pharmaceuticals. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Nvidia slid 7.7% after hours while AMD and Broadcom rose — the AI trade changed hands, it didn't breakNvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
Author  Irene Q.
Nov 12, Thu
Nvidia closed Wednesday at 173.73, up 2.87%, then fell as much as 8.1% to 159.44 after reports that its board was preparing for a possible leadership change. The same session, the Philadelphia Semiconductor Index rose 5.7% with all 30 components higher, CoreWeave jumped 24.7% on 168% revenue growth, and Micron added 11.9%. If AI demand were being repriced, AMD and Broadcom would not be bid. This is a governance discount on one name, and 204.54 — the 200-day average — is the level that settles it.
placeholder
Gold hit a one-year low while central banks bought 321 tonnes — the sellers were never the ones you thinkSpot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
Author  Irene Q.
Nov 13, Fri
Spot gold closed at 3,876 on Thursday, down 2.8% and its lowest close in more than a year, with an intraday low near 3,852. The dollar is at a 19-month high of 103.21 and the 10-year yield is at 5.10%, so the price move is easy to explain. What is harder to explain is who sold: central banks bought 321 tonnes in Q3, the PBoC added for a 24th straight month, ETF holdings are near a record 4,256 tonnes, and roughly 95% of the futures selling came from non-reportable and sovereign-type accounts rather than hedge funds. This piece separates the two books that have to balance.
placeholder
Brent rose 3.3% and US crude stocks built 4.66 million barrels in the same weekBrent January settled at 95.82, up 3.3%, and WTI at 88.74, up 2.55%, after the US signalled it would not pursue a deal with Iran and attacks on Gulf shipping continued. In the same week, EIA data showed US crude inventories rising 4.657 million barrels against expectations of a 1.1 million draw, with gasoline up another 1.799 million. OPEC output also rebounded 1.96 million barrels a day to 27.16 million in October, led by Saudi Arabia at 10.56 million. This piece separates the geopolitical premium from the physical balance and lays out where each side of the trade is anchored.
Author  Irene Q.
Nov 13, Fri
Brent January settled at 95.82, up 3.3%, and WTI at 88.74, up 2.55%, after the US signalled it would not pursue a deal with Iran and attacks on Gulf shipping continued. In the same week, EIA data showed US crude inventories rising 4.657 million barrels against expectations of a 1.1 million draw, with gasoline up another 1.799 million. OPEC output also rebounded 1.96 million barrels a day to 27.16 million in October, led by Saudi Arabia at 10.56 million. This piece separates the geopolitical premium from the physical balance and lays out where each side of the trade is anchored.
placeholder
Anthropic is six times oversubscribed at $1.4 trillion while Nvidia is down 32% — the AI trade has two pricesAnthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
Author  Irene Q.
7 hours ago
Anthropic lists on Nasdaq as ANT on Thursday at $70 ~ $78 a share, raising up to $64.4 billion at a target valuation near $1.4 trillion, and the book is reportedly six times covered. In the same six weeks, Nvidia has fallen 32% and the QQQ is 10.9% below its October peak. Private capital and public markets are marking the same AI complex at two very different prices. This piece separates the two books: what the S-1 shows, who is anchoring the $26 billion private placement, and what Thursday's debut would have to do to change the public tape.
placeholder
Gold Price Analysis Today | Forex Gold Analysis | XAU/USD Analysis - November 16, 2026Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
Author  Mitrade
6 hours ago
Get the latest gold price analysis, forex gold insights, and XAU/USD analysis for November 16, 2026. Read on for the details.
goTop
quote